INCYIncyte Corp.
$114.23
$2.48
(2.13%)
Closed $114.23
$0.23
(0.20%)
After Hours
EarningsJul 28
Mkt Cap$23.32B
Vol1.48M
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patients with von Willebrand disease.read more...
Benzinga
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being...
Business Wire
Incyte to Report Second Quarter Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET...
Business Wire
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding...
Business Wire
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Zacks
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
A breakout could be in the cards for this biopharmaceutical play, says Carter Worth
Shares of Incyte are now moving out of a seven-month range...
CNBC: Top News
Incyte Announces Positive CHMP Opinion for Opzelura (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients...
Business Wire
Incyte's Minjuvi Approved In Japan For Relapsed Or Refractory DLBCL
(RTTNews) - Incyte Biosciences (INCY) in Japan announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL...
Nasdaq News: Markets
<
1
2
...
>
Advertisement|Remove ads.
Latest INCY News
ViewIncyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Benzinga
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Business Wire
Incyte to Report Second Quarter Financial Results
Business Wire
Advertisement|Remove ads.